RxDoctor Payments Data

Anna Zakharova

Physician Assistant · Spokane, WANPI 1891344172

Payments from drug & device makers

$2,271in general payments, 2019–2025

Across 69 payments — averaging $32.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$290
  • AstraZeneca$248
  • Novo Nordisk$201
  • Abbott$194
  • Boehringer Ingelheim$194
  • Novartis$188
  • plus $958 from 15 others

What the payments were for

  • Food & beverage$2,271100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,271 in reported general payments places this provider in the 90th percentile of 2,741 physician assistant providers in Washington.

See all physician assistant providers in Washington

Medicare billing

Part B allowed, 2024
$35,337
Medicare patients
182
Services billed
410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin134$117,751
EntrestoSacubitril/Valsartan120$107,875
EliquisApixaban37$26,541
FarxigaDapagliflozin Propanediol29$20,775
Torsemide190$3,296
Potassium Chloride109$1,891
Metoprolol Succinate112$1,433
Eplerenone14$1,157
Bisoprolol Fumarate25$838
Digoxin27$512
Spironolactone66$484
Rosuvastatin Calcium33$477
Carvedilol50$409
Valsartan24$399
Ezetimibe12$355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$194$117,751134 claims
NovartisEntresto$188$107,875120 claims
PfizerEliquis$108$26,54137 claims
AstraZenecaFarxiga$248$20,77529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,741 physician assistant providers in Washington.

Other physician assistant in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →